Current challenges for the diagnosis of HFpEF and possible simplification of the diagnostic approach.

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular Pharmacology Pub Date : 2025-09-11 DOI:10.1097/FJC.0000000000001755

Marco Bernardi, Michele Golino, Luigi Spadafora, Gianmarco Sarto, Maurizio Forte, Beatrice Simeone, Erica Rocco, Valentina Valenti, Sonia Schiavon, Antonio Esposito, Elena Di Florio, Lorenzo Scalia, Lorenzo Lo Sasso, Giacomo Frati, Giuseppe Biondi Zoccai, Francesco Versaci, Sebastiano Sciarretta

{"title":"Current challenges for the diagnosis of HFpEF and possible simplification of the diagnostic approach.","authors":"Marco Bernardi, Michele Golino, Luigi Spadafora, Gianmarco Sarto, Maurizio Forte, Beatrice Simeone, Erica Rocco, Valentina Valenti, Sonia Schiavon, Antonio Esposito, Elena Di Florio, Lorenzo Scalia, Lorenzo Lo Sasso, Giacomo Frati, Giuseppe Biondi Zoccai, Francesco Versaci, Sebastiano Sciarretta","doi":"10.1097/FJC.0000000000001755","DOIUrl":null,"url":null,"abstract":"<p><p>Heart failure with preserved ejection fraction (HFpEF) is a prevalent and multifaceted clinical syndrome, often underdiagnosed due to its heterogeneous presentation and overlapping comorbidities. Recent randomized trials have demonstrated the efficacy of sodium-glucose co-transporter 2 (SGLT2) inhibitors in reducing heart failure hospitalizations and cardiovascular mortality. In this review, we analyze the main challenges of HFpEF diagnosis and discuss current diagnostic algorithms. Based on recent evidence and recommendations, we propose a possible way to simplify and accelerate the diagnostic process of HFpEF, to support an early initiation of disease-modifying therapies. An interactive web-based version of the proposed algorithm is available at www.hfpefdiagnosis.com for research or exploratory purposes.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/FJC.0000000000001755","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a prevalent and multifaceted clinical syndrome, often underdiagnosed due to its heterogeneous presentation and overlapping comorbidities. Recent randomized trials have demonstrated the efficacy of sodium-glucose co-transporter 2 (SGLT2) inhibitors in reducing heart failure hospitalizations and cardiovascular mortality. In this review, we analyze the main challenges of HFpEF diagnosis and discuss current diagnostic algorithms. Based on recent evidence and recommendations, we propose a possible way to simplify and accelerate the diagnostic process of HFpEF, to support an early initiation of disease-modifying therapies. An interactive web-based version of the proposed algorithm is available at www.hfpefdiagnosis.com for research or exploratory purposes.

查看原文本刊更多论文

当前HFpEF诊断的挑战和可能简化的诊断方法。

心力衰竭伴保留射血分数（HFpEF）是一种普遍且多方面的临床综合征，由于其异质的表现和重叠的合并症，经常被误诊。最近的随机试验已经证明了钠-葡萄糖共转运蛋白2 （SGLT2）抑制剂在降低心力衰竭住院率和心血管死亡率方面的有效性。在这篇综述中，我们分析了HFpEF诊断的主要挑战，并讨论了目前的诊断算法。基于最近的证据和建议，我们提出了一种可能的方法来简化和加速HFpEF的诊断过程，以支持早期启动疾病改善治疗。所提出的算法的交互式网络版本可在www.hfpefdiagnosis.com上获得，用于研究或探索目的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cardiovascular Pharmacology 医学-心血管系统

CiteScore

5.10

自引率

3.30%

发文量

367

审稿时长

1 months

期刊介绍： Journal of Cardiovascular Pharmacology is a peer reviewed, multidisciplinary journal that publishes original articles and pertinent review articles on basic and clinical aspects of cardiovascular pharmacology. The Journal encourages submission in all aspects of cardiovascular pharmacology/medicine including, but not limited to: stroke, kidney disease, lipid disorders, diabetes, systemic and pulmonary hypertension, cancer angiogenesis, neural and hormonal control of the circulation, sepsis, neurodegenerative diseases with a vascular component, cardiac and vascular remodeling, heart failure, angina, anticoagulants/antiplatelet agents, drugs/agents that affect vascular smooth muscle, and arrhythmias. Appropriate subjects include new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects, application of drugs to gain novel insights into physiology or pathological conditions, clinical results with new and established agents, and novel methods. The focus is on pharmacology in its broadest applications, incorporating not only traditional approaches, but new approaches to the development of pharmacological agents and the prevention and treatment of cardiovascular diseases. Please note that JCVP does not publish work based on biological extracts of mixed and uncertain chemical composition or unknown concentration.